Tom van Meerten
dr.
I am a hematologist involved in patient care, clinical and translation research in the field of malignant lymphoma. I focus on translational medicine on diffuse large B cell lymphoma and mantle cell lymphoma. My question by all our findings: how does the patient profit or does it help me to treat the patients. The focus of my research group is on DNA repair, cell cycle and cell death. We test novel combinations of existing anti-cancer agents to ultimately improve the treatment of patients suffering from lymphoma. I participate in the organization of new clinical trials both international (European Mantle cell Lymphoma Network) and national (HOVON). Moreover, I am actively involved in clinical trials concerning the application of CAR T cells for patient with lymphoma.
Lactate dehydrogenase levels and F-18-FDG PET/CT metrics differentiate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma
Published in: Nuclear Medicine Communications
Access to document
10.1097/MNM.0000000000000840
document
PURPOSE: This study aims to investigate whether clinical, laboratory, and fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT findings can discriminate between mediastinal Hodgkin’s lymphoma and primary mediastinal B-cell lymphoma (PMBCL). PATIENTS AND METHODS: This retrospective study included 56 patients (42 with mediastinal Hodgkin’s lymphoma and 14 with PBMCL). Differences in clinical, laboratory, and F-FDG PET/CT metrics were assessed between Hodgkin’s lymphoma and PMBCL. RESULTS: Lactate dehydrogenase (LDH) and F-FDG PET/CT-based maximum tumor diameter, lesion-to-liver ratio maximum standardized uptake value (SUVmax), and lesion-to-liver ratio peak standardized uptake value (SUVpeak) were all significantly higher...
Rayan H M Alkhawtani, Walter Noordzij, Andor W J M Glaudemans, Rozemarijn S van Rijn, Hilde T van der Galiën, Hans Balink, Marcel Nijland, Hugo J A Adams, Gerwin Huls, Tom van Meerten, Thomas C Kwee
Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma
Published in: Annals of Hematology
Access to document
10.1007/s00277-018-3233-9
document
Marcel Nijland, Tom van Meerten, Annika Seitz, Gerwin Huls, Robby Kibbelaar, Lydia Visser, Anke van den Berg, Arjan Diepstra
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0193098
document
Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs can be safely combined to improve standard therapy without antagonizing anti-CD20 efficacy. In this study, we aimed to identify rituximab compatible drug-target combinations for DLBCL. For this, we collected gene expression profiles of 1,804 DLBCL patient samples. Subsequently, we performed a guilt-by-association analysis with...
Mathilde R. W. de Jong, Lydia Visser, Gerwin Huls, Arjan Diepstra, Marcel van Vugt, Emanuele Ammatuna, Rozemarijn S. van Rijn, Edo Vellenga, Anke van den Berg, Rudolf S. N. Fehrmann, Tom van Meerten
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review
Filipe Montes de Jesus, Thomas Kwee, Marcel Nijland, Xaver-Ulrich Kahle, Geert Huls, Rudi Dierckx, Tom van Meerten, Olivier Gheysens, D Dierickx, Walter Noordzij, Andor W.J.M. Glaudemans
CD20-selective inhibition of CD47-SIRP alpha “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab
Published in: OncoImmunology
Access to document
10.1080/2162402X.2017.1386361
document
Here, we report on a novel bispecific antibody-derivative, designated RTX-CD47, with unique capacity for CD20-directed inhibition of CD47-SIRP alpha “don’t eat me” signaling. RTX-CD47 comprises a CD20-targeting scFv antibody fragment derived from rituximab fused in tandem to a CD47-blocking scFv. Single agent treatment with RTX-CD47 triggered significant phagocytic removal of CD20(pos)/CD47(pos) malignant B-cells, but not of CD20(neg)/CD47(pos) cells, and required no pro-phagocytic FcR-mediated signaling. Importantly, treatment with RTX-CD47 synergistically enhanced the phagocytic elimination of primary malignant B cells by autologous phagocytic effector cells as induced by therapeutic anticancer...
Peter E. van Bommel, Yuan He, Ilona Schepel, Mark A. J. M. Hendriks, Valerie R. Wiersma, Robert J. van Ginkel, Tom van Meerten, Emanuele Ammatuna, Gerwin Huls, Douwe F. Samplonius, Wijnand Helfrich, Edwin Bremer